Shares of Tempus AI (NASDAQ: TEM), a leading AI-driven precision medicine company, surged 5.04% on Thursday, following the company's announcement that it will present nine abstracts at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting.
The abstracts, spanning various aspects of Tempus' research and development efforts, highlight the company's advancements in harnessing the power of AI and multimodal data to drive immunotherapy innovation and improve patient outcomes.
Among the key presentations, Tempus will unveil a novel multi-omic algorithm, called the Immune Profile Score (IPS), designed to stratify patient outcomes to immune checkpoint inhibitors, a widely used class of cancer immunotherapies. The company's study aims to validate the IPS algorithm's ability to predict treatment response, potentially enabling more personalized and effective immunotherapy strategies.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。